NEW YORK (GenomeWeb News) – Eutropics said today that it will use its companion diagnostic methodology to help Tolero Pharmaceuticals develop therapeutics for hematological malignancies.

Under the terms of the agreement, Eutropics will use its Praedicare-Dx biomarker platform to support the development of Tolero's alvocidibm, a Phase III compound that has demonstrated clinical activity in patients with acute myelogenous leukemia and chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.